Vasilev D, Katsarova M, Dikov I, Rachev E
Akush Ginekol (Sofiia). 1990;29(1):79-83.
After a brief review of the qualities of the new triphasic contraceptive preparation Trisistone and some of its advantages in comparison with the other combined contraceptive drugs the authors report on the results from the first study, carried out in our country, on the therapeutic effect of Trisistone. Thirty-eight women with various gynecological diseases were treated. The largest group was that of women with irregular bleedings. In this group the effect was not good in all women. It was found that Trisistone had limited possibilities to control irregular uterine bleedings, which most probably was connected with its comparatively low dose of steroid hormones. The side effects were comparatively slight and not quite frequently. The most frequent side effect was the occurrence of irregular bleeding in 9.5% of the treated women. The state without any side effects was improved in 30.1% of the patients. Best results were found in women with postcastration syndrome, hypoestrogenism and congenital anomalies in the development of ovaries--primary ovarian dysgenesis. Trisistone is especially suitable for substituted treatment in women with ovarian hormonal deficit.
在简要回顾新型三相避孕制剂曲司氯铵的特性及其与其他复方避孕药相比的一些优势后，作者报告了在我国进行的关于曲司氯铵治疗效果的第一项研究结果。对38名患有各种妇科疾病的女性进行了治疗。人数最多的一组是月经不调的女性。在这组中，并非所有女性的治疗效果都良好。发现曲司氯铵控制子宫不规则出血的可能性有限，这很可能与其相对较低剂量的甾体激素有关。副作用相对较轻且不常见。最常见的副作用是9.5%的接受治疗的女性出现不规则出血。30.1%的患者无任何副作用的状况得到改善。在去势后综合征、雌激素缺乏症以及卵巢发育先天性异常——原发性卵巢发育不全的女性中发现了最佳效果。曲司氯铵特别适用于卵巢激素缺乏女性的替代治疗。
